Could a Drug Help Preserve Hearing Health?
Scientists from the University of California San Francisco (UCSF) identified a gene that links deafness to cell death in the inner ear.
Scientists from the University of California San Francisco (UCSF) identified a gene that links deafness to cell death in the inner ear.
Creighton University's Translational Hearing Center has been awarded “the largest National Institutes of Health (NIH) grant in the university’s history,” according to an announcement from the Nebraska-based school.
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a clinical-stage biotech company which specializes...
Data from the presented studies showed that SENS-401 protected inner ear function and enhanced sensory hair cell survival in preclinical models of acoustic trauma and, separately, cisplatin infusion.
Read MoreThe study showed that STS administered six hours after Cisplatin could reduce the severity of hearing loss without affecting the chance of cure for the cancer.
Read MoreThe company’s most advanced drug candidate ACOU085 is being developed for clinical application in otoprotection (cisplatin-related) and will be profiled in functional improvement of hair cells.
Read MoreAccording to the FDA, Breakthrough Therapy designation is given when preliminary clinical evidence has been provided to show that a treatment effect may represent substantial improvement over available therapies for the treatment of a serious condition.
Read MoreSENS-401, R-azasetron besylate, is a drug candidate that aims to protect and preserve inner ear tissue when lesions are present that can cause progressive or sequelar hearing impediments.
Read MoreUsing a highly sensitive technique to measure and map cisplatin in mouse and human inner ear tissues, researchers found that forms of cisplatin build up in the inner ear.
Read MoreUsing a new technique to deliver steroids to the inner ear, developed with funding from Action on Hearing Loss, Otomagnetics has been able to reduce hearing loss in mice treated with the chemotherapy drug cisplatin by 50%.
Read MoreThe drug is a therapy in development for the treatment of hearing disorders, for the prevention of Platinum-Induced Ototoxicity in pediatric patients.
Read MoreOtonomy has announced the enrollment of the first patients in a Phase 2 clinical trial evaluating OTO-104 for the prevention of hearing loss in cancer patients undergoing chemotherapy with platinum-based agents.
Read MoreMany testicular cancer survivors experience hearing loss after cisplatin-based chemotherapy, according to researchers at Indiana University, who found that increased doses of cisplatin were associated with increased hearing loss.
Read MoreSt. Jude Children’s Research Hospital scientists have found that variations of inherited genes are associated with hearing loss in young cancer patients treated with cisplatin, a drug widely used to treat brain tumors and other types of cancer.
Read MoreIn the General Session of the 2014 Academy of Doctors of Audiology (ADA) Convention held November 6-9, 2014 in Las Vegas, Kathleen Campbell, PhD, of Southern Illinois University School of Medicine, gave an interesting and lively talk on ototoxicity and the role of pharmaceutical agents in hearing loss management and prevention.
Read More